Wasp venom immunotherapy changes IgG antibody specificity

Michils, Alain; Ledent, C.; Mairesse, M.; Gossart, Béatrice; Duchateau, Jean

doi:10.1111/j.1365-2222.1997.tb01255.x

Cited by 16 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have not been able to find significant alterations in IgG or IgG4 avidity by aeroallergen SIT [14, 29], which have been shown in insect venom studies [30, 31]. This supports that IgG4 contributes to the blocking activity by simple quantity rather than altered quality [32, 33].…”

Section: Discussionsupporting

confidence: 49%

Is Immunotherapy-Induced Birch-Pollen-Specific IgG4 a Marker for Decreased Allergen-Specific Sensitivity?

Bødtger

Ejrnaes²,

Hummelshøj³

et al. 2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The role of IgG4 during allergen-specific immunotherapy (SIT) is still controversial. The available studies present paramount differences in in vitro techniques, allergens, and clinical outcome parameters. By implementing a sensitive method, and pivotal clinical outcome parameters, we wanted to ascertain the utility of IgG4 as a clinical marker of decreased allergen-specific sensitivity to a common aeroallergen. Methods: Sera were drawn from 23 birch-pollen-allergic patients during a placebo-controlled clinical trial on birch pollen SIT. Seventeen patients received active treatment. Blood samples were drawn at 0, 2, 4, 7, and 30 treatment weeks, and 36 months. The binding activity of autologous IgG, IgG4, IgE, and IgE- and/or IgG-depleted serum to ¹²⁵I-labelled recombinant Bet v 1 was assessed in a fluid-phase radioimmunoassay. Disease severity was assessed subjectively on a visual analogue scale (VAS), and objectively by intradermal late-phase reaction diameters. Results: Before SIT IgG4 fraction of IgG-allergen binding varied from 4 to 74%, with a median of 36%, increasing to 71% after 36 months. Changes in IgG4 or IgG4/IgG fraction were not correlated to clinical outcome parameters. Changes in IgG allergen binding and VAS were significantly correlated (σ = 0.72; p < 0.05). SIT increased the serum-blocking activity of IgE allergen binding from 25% before SIT to 80% after SIT. No changes were observed in the placebo group. Conclusion: The data suggest that IgG4 per se is a poor marker of decreased allergen-specific sensitivity to birch pollen, both as a single measurement and as delta values.

show abstract

Section: Discussionsupporting

confidence: 49%

Is Immunotherapy-Induced Birch-Pollen-Specific IgG4 a Marker for Decreased Allergen-Specific Sensitivity?

Bødtger

Ejrnaes²,

Hummelshøj³

et al. 2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…A change in IgE specificity has also been documented during grass pollen immunotherapy [ 22]. Furthermore, these early results emphasize that, even when established, antigenic immunodominance of IgG antibody is not a permanent state and can be reversed by intervention on the immune system, for example, through the injection large amounts of antigens [ 23–25].…”

Section: Discussionmentioning

confidence: 98%

Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model

Michils

Vervier

Choufani³

et al. 1999

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Similarly, Michils et al [7] reported that an increase in specific IgG during venom SIT was associated with a rapid change in antibody specificity. Interestingly, the allergen binding of pooled IgG fractions from allergic individuals was inhibited to a greater extent by sera from other allergic patients than by sera from SIT patients, despite higher antibody titres in the latter.…”

Section: Immunotherapy-induced Changes In Igg Specificitymentioning

confidence: 95%

“…However, a correlation between increases in IgG4 titres and clinical improvement has not always been found [4,5]. One explanation for this is provided by increasing evidence that suggests that the biological activity as well as the quantity of IgG4 antibodies is altered during successful SIT [6][7][8]. SIT-induced IgG4 antibodies thus have IgE blocking activities that are not necessarily reflected in the antibody titre but require biological assays for detection [6, [9][10][11][12].…”

Section: Introductionmentioning

confidence: 97%

Mechanisms of immunotherapy: IgG revisited

Wachholz

Durham

2004

Current Opinion in Allergy &Amp; Clinical Immunology

175

136

View full text Add to dashboard Cite

Successful immunotherapy is associated with quantitative and qualitative changes in the allergen-specific IgG antibody response. The induction of IgG antibodies with blocking activity may have a protective role not only through the inhibition of allergen-induced, IgE-mediated release of inflammatory mediators from mast cells and basophils, but also through the inhibition of IgE-facilitated antigen presentation to T cells. Qualitative changes in the allergen-specific IgG antibody response may possibly be an important mechanism underlying the clinical efficacy of specific immunotherapy. Monitoring changes in blocking activity using cellular assays may give an early indication of the potential success of treatment.

show abstract

Wasp venom immunotherapy changes IgG antibody specificity

Cited by 16 publications

References 40 publications

Is Immunotherapy-Induced Birch-Pollen-Specific IgG4 a Marker for Decreased Allergen-Specific Sensitivity?

Is Immunotherapy-Induced Birch-Pollen-Specific IgG4 a Marker for Decreased Allergen-Specific Sensitivity?

Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model

Mechanisms of immunotherapy: IgG revisited

Contact Info

Product

Resources

About